90 related articles for article (PubMed ID: 19209155)
1. Unexpected autocrine role of vascular endothelial growth factor in squamous cell carcinoma.
Arbiser JL
J Invest Dermatol; 2009 Mar; 129(3):538-40. PubMed ID: 19209155
[TBL] [Abstract][Full Text] [Related]
2. 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib.
Desar IM; Stillebroer AB; Oosterwijk E; Leenders WP; van Herpen CM; van der Graaf WT; Boerman OC; Mulders PF; Oyen WJ
J Nucl Med; 2010 Nov; 51(11):1707-15. PubMed ID: 20956472
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
Rini BI
Clin Cancer Res; 2007 Feb; 13(4):1098-106. PubMed ID: 17317817
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis regulated by VEGF and its receptors and its clinical application.
Shibuya M
Rinsho Ketsueki; 2009 May; 50(5):404-12. PubMed ID: 19483401
[No Abstract] [Full Text] [Related]
5. [New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology].
Hagymási K; Tulassay Z
Orv Hetil; 2010 Oct; 151(43):1763-8. PubMed ID: 20940115
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis as a therapeutic target in urothelial carcinoma.
Pinto A; Redondo A; Zamora P; Castelo B; Espinosa E
Anticancer Drugs; 2010 Nov; 21(10):890-6. PubMed ID: 20729712
[TBL] [Abstract][Full Text] [Related]
7. How well do angiogenesis inhibitors work? Biomarkers of response prove elusive.
Brower V
J Natl Cancer Inst; 2009 Jun; 101(12):846-7. PubMed ID: 19509354
[No Abstract] [Full Text] [Related]
8. Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma.
Peng S; Wang Y; Peng H; Chen D; Shen S; Peng B; Chen M; Lencioni R; Kuang M
Hepatology; 2014 Oct; 60(4):1264-77. PubMed ID: 24849467
[TBL] [Abstract][Full Text] [Related]
9. It takes two to tango: combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factor-vascular endothelial growth factor receptor pathway in patients with solid malignancies.
Boere IA; Hamberg P; Sleijfer S
Cancer Sci; 2010 Jan; 101(1):7-15. PubMed ID: 19860846
[TBL] [Abstract][Full Text] [Related]
10. Signaling inhibitors in metastatic renal cell carcinoma.
Escudier B
Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
[TBL] [Abstract][Full Text] [Related]
11. [Squamous cell carcinoma in a patient receiving sorafenib].
Adnot-Desanlis L; Bernard P; Reguiaï Z
Ann Dermatol Venereol; 2011 Feb; 138(2):120-3. PubMed ID: 21333823
[TBL] [Abstract][Full Text] [Related]
12. Anti-angiogenic therapy: concept to clinic.
Young RJ; Reed MW
Microcirculation; 2012 Feb; 19(2):115-25. PubMed ID: 22078005
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors.
Schultheis B; Neumann H; Roy R; Heuer V; Kummer G; Strumberg D
Int J Clin Pharmacol Ther; 2012 Jan; 50(1):72-3. PubMed ID: 22192652
[No Abstract] [Full Text] [Related]
14. Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development.
Rini BI; Sosman JA; Motzer RJ
BJU Int; 2005 Aug; 96(3):286-90. PubMed ID: 16042715
[No Abstract] [Full Text] [Related]
15. [Anti-angiogenic drugs].
Sato Y
Nihon Rinsho; 2010 Jun; 68(6):1054-8. PubMed ID: 20535955
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.
Rini BI
Cancer; 2009 May; 115(10 Suppl):2306-12. PubMed ID: 19402073
[TBL] [Abstract][Full Text] [Related]
17. Combination of hypoxia and RNA-interference targeting VEGF induces apoptosis in hepatoma cells via autocrine mechanisms.
Raskopf E; Vogt A; Decker G; Hirt S; Daskalow K; Cramer T; Standop J; Gonzalez-Carmona MA; Sauerbruch T; Schmitz V
Curr Pharm Biotechnol; 2012 Sep; 13(11):2290-8. PubMed ID: 21605070
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy for metastatic renal cell carcinoma.
Motzer RJ; Bukowski RM
J Clin Oncol; 2006 Dec; 24(35):5601-8. PubMed ID: 17158546
[TBL] [Abstract][Full Text] [Related]
19. Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma.
Cho DC; Puzanov I; Regan MM; Schwarzberg T; Seery V; Lee MY; Liu V; Bhatt R; Koon H; Mier JW; Sosman JA; Atkins MB; McDermott DF
J Immunother; 2009; 32(2):181-5. PubMed ID: 19238017
[TBL] [Abstract][Full Text] [Related]
20. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]